Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm

Virulence

Volumn 4, Issue 3, 2013, Pages 223-229

  Soto, Sara M ^a  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

Antimicrobial resistance; Biofilm; Efflux pump inhibitors; Efflux pumps; RND family

Indexed keywords

ABC TRANSPORTER; BETA LACTAM; CHLORAMPHENICOL; EFFLUX PUMP; FLUCONAZOLE; MEMBRANE PROTEIN; QUINOLONE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM; BIOFILM; CANDIDA ALBICANS; DRUG DIFFUSION; ESCHERICHIA COLI; GENE EXPRESSION; LISTERIA MONOCYTOGENES; LISTERIOSIS; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PLANKTON; PROTON MOTIVE FORCE; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS;

EID: 84875955724     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.23724     Document Type: Article

References (83)

1. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15:167-93; PMID:11932229; http://dx.doi.org/10.1128/CMR.15.2.167-193.2002
2. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010; 35:322-32; PMID:20149602; http://dx.doi.org/10.1016/j.ijantimicag. 2009.12.011
3. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents 1999; 11:217-21, discussion 237-9; PMID:10394973; http://dx.doi.org/10.1016/S0924-8579(99)00018-7
4. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22; PMID:10334980; http://dx.doi. org/10.1126/science.284.5418.1318
5. Potera C. Forging a link between biofilms and disease. Science 1999; 283:1837-9, 1839; PMID:10206887; http://dx.doi.org/10.1126/science.283.5409.1837
6. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol 2002; 56:187-209; PMID:12142477; http://dx.doi.org/10.1146/annurev. micro.56.012302.160705
7. Kaplan JB. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. J Dent Res 2010; 89:205-18; PMID:20139339; http://dx.doi. org/10.1177/0022034509359403
8. Webb JS, Thompson LS, James S, Charlton T, Tolker-Nielsen T, Koch B, et al. Cell death in Pseudomonas aeruginosa biofilm development. J Bacteriol 2003; 185:4585-92; PMID:12867469; http://dx.doi. org/10.1128/JB.185.15.4585-4592.2003
9. Hoyle BD, Costerton JW. Bacterial resistance to antibiotics: the role of biofilms. Prog Drug Res 1991; 37:91-105; PMID:1763187.
10. Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2000; 44:1818-24; PMID:10858336; http://dx.doi.org/10.1128/ AAC.44.7.1818-1824.2000
11. Brown MR, Allison DG, Gilbert P. Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? J Antimicrob Chemother 1988; 22:777-80; PMID:3072331; http://dx.doi.org/10.1093/ jac/22.6.777
12. rd, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47:317-23; PMID:12499208; http://dx.doi. org/10.1128/AAC.47.1.317-323.2003
13. Brooun A, Liu S, Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2000; 44:640-6; PMID:10681331; http://dx.doi.org/10.1128/ AAC.44.3.640-646.2000
14. Gilbert P, Allison DG, McBain AJ. Biofilms in vitro and in vivo: do singular mechanisms imply cross-resistance? J Appl Microbiol 2002; 92(Suppl):98S-110S; PMID:12000619; http://dx.doi.org/10.1046/j.1365-2672.92.5s1.5.x
15. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007; 5:48-56; PMID:17143318; http://dx.doi.org/10.1038/nrmicro1557
16. Pearson JP, Van Delden C, Iglewski BH. Active efflux and diffusion are involved in transport of Pseudomonas aeruginosa cell-to-cell signals. J Bacteriol 1999; 181:1203-10; PMID:9973347.
17. Lee A, Mao W, Warren MS, Mistry A, Hoshino K, Okumura R, et al. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol 2000; 182:3142-50; PMID:10809693; http://dx.doi.org/10.1128/ JB.182.11.3142-3150.2000
18. Piddock LJ. Multidrug-resistance efflux pumps-not just for resistance. Nat Rev Microbiol 2006; 4:629-36; PMID:16845433; http://dx.doi.org/10.1038/nrmicro1464
19. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19:382-402; PMID:16614254; http://dx.doi.org/10.1128/CMR.19.2.382-402.2006
20. Lubelski J, Konings WN, Driessen AJ. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev 2007; 71:463-76; PMID:17804667; http://dx.doi. org/10.1128/MMBR.00001-07
21. Pao SS, Paulsen IT, Saier MH Jr. Major facilitator superfamily. Microbiol Mol Biol Rev 1998; 62:1-34; PMID:9529885.
22. Kuroda T, Tsuchiya T. Multidrug efflux transporters in the MATE family. Biochim Biophys Acta 2009; 1794:763-8; PMID:19100867; http://dx.doi. org/10.1016/j.bbapap.2008.11.012
23. Jack DL, Yang NM, Saier MH Jr. The drug/metabolite transporter superfamily. Eur J Biochem 2001; 268:3620-39; PMID:11432728; http://dx.doi. org/10.1046/j.1432-1327.2001.02265.x
24. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004; 64:159-204; PMID:14717618; http://dx.doi.org/10.2165/00003495-200464020-00004
25. Nikaido H, Takatsuka Y. Mechanisms of RNDmultidrug efflux pumps. Bioch Bioph Acta 2009; 1794:769-81; http://dx.doi.org/10.1016/j.bbapap.2008.10.004
26. Seeger MA, Diederichs K, Eicher T, Brandstätter L, Schiefner A, Verrey F, et al. The AcrB efflux pump: conformational cycling and peristalsis lead to multidrug resistance. Curr Drug Targets 2008; 9:729-49; PMID:18781920; http://dx.doi. org/10.2174/138945008785747789
27. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 2009; 69:1555-623; PMID:19678712; http://dx.doi. org/10.2165/11317030-000000000-00000
28. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cellto-cell signals in the development of a bacterial biofilm. Science 1998; 280:295-8; PMID:9535661; http:// dx.doi.org/10.1126/science.280.5361.295
29. Parsek MR, Greenberg EP. Sociomicrobiology: the connections between quorum sensing and biofilms. Trends Microbiol 2005; 13:27-33; PMID:15639629; http:// dx.doi.org/10.1016/j.tim.2004.11.007
30. De Kievit TR, Parkins MD, Gillis RJ, Srikumar R, Ceri H, Poole K, et al. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2001; 45:1761-70; PMID:11353623; http://dx.doi.org/10.1128/AAC.45.6.1761-1770.2001
31. Chan YY, Chua KL. The Burkholderia pseudomallei BpeAB-OprB efflux pump: expression and impact on quorum sensing and virulence. J Bacteriol 2005; 187:4707-19; PMID:15995185; http://dx.doi. org/10.1128/JB.187.14.4707-4719.2005
32. Diggle SP, Winzer K, Lazdunski A, Williams P, Cámara M. Advancing the quorum in Pseudomonas aeruginosa: MvaT and the regulation of N-acylhomoserine lactone production and virulence gene expression. J Bacteriol 2002; 184:2576-86; PMID:11976285; http://dx.doi. org/10.1128/JB.184.10.2576-2586.2002
33. Hocquet D, Berthelot P, Roussel-Delvallez M, Favre R, Jeannot K, Bajolet O, et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 2007; 51:3531-6; PMID:17682106; http://dx.doi.org/10.1128/ AAC.00503-07
34. Nichols WW, Evans MJ, Slack MP, Walmsley HL. The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J Gen Microbiol 1989; 135:1291-303; PMID:2516117.
35. Darouiche RO, Dhir A, Miller AJ, Landon GC, Raad II, Musher DM. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. J Infect Dis 1994; 170:720-3; PMID:7915751; http:// dx.doi.org/10.1093/infdis/170.3.720
36. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008; 68:223-40; PMID:18312276; http://dx.doi.org/10.1111/j.1365-2958.2008.06152.x
37. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27(Suppl 1):S93-9; PMID:9710677; http://dx.doi.org/10.1086/514909
38. Li XZ, Nikaido H, Poole K. Role of mexA-mexBoprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39:1948-53; PMID:8540696; http://dx.doi.org/10.1128/ AAC.39.9.1948
39. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, et al. Overexpression of the mexC-mexDoprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996; 21:713-24; PMID:8878035; http://dx.doi. org/10.1046/j.1365-2958.1996.281397.x
40. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC. Characterization of MexEMexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997; 23:345-54; PMID:9044268; http://dx.doi. org/10.1046/j.1365-2958.1997.2281594.x
41. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43:415-7; PMID:9925549.
42. Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP, Iglewski BH. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2005; 49:3858-67; PMID:16127063; http://dx.doi.org/10.1128/ AAC.49.9.3858-3867.2005
43. Zhang L, Mah TF. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol 2008; 190:4447-52; PMID:18469108; http://dx.doi. org/10.1128/JB.01655-07
44. Chiang WC, Pamp SJ, Nilsson M, Givskov M, Tolker-Nielsen T. The metabolically active subpopulation in Pseudomonas aeruginosa biofilms survives exposure to membrane-targeting antimicrobials via distinct molecular mechanisms. FEMS Immunol Med Microbiol 2012; 65:245-56; PMID:22251216; http://dx.doi. org/10.1111/j.1574-695X.2012.00929.x
45. Ito A, Taniuchi A, May T, Kawata K, Okabe S. Increased antibiotic resistance of Escherichia coli in mature biofilms. Appl Environ Microbiol 2009; 75:4093-100; PMID:19376922; http://dx.doi. org/10.1128/AEM.02949-08
46. Webber MA, Piddock LJ. Absence of mutations in mar-RAB or soxRS in acrB-overexpressing fluoroquinoloneresistant clinical and veterinary isolates of Escherichia coli. Antimicrob Agents Chemother 2001; 45:1550-2; PMID:11302826; http://dx.doi.org/10.1128/ AAC.45.5.1550-1552.2001
47. Fernandes P, Ferreira BS, Cabral JM. Solvent tolerance in bacteria: role of efflux pumps and crossresistance with antibiotics. Int J Antimicrob Agents 2003; 22:211-6; PMID:13678823; http://dx.doi. org/10.1016/S0924-8579(03)00209-7
48. Bailey AM, Webber MA, Piddock LJ. Medium plays a role in determining expression of acrB, marA, and soxS in Escherichia coli. Antimicrob Agents Chemother 2006; 50:1071-4; PMID:16495271; http://dx.doi. org/10.1128/AAC.50.3.1071-1074.2006
49. White DG, Maneewannakul K, von Hofe E, Zillman M, Eisenberg W, Field AK, et al. Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs. Antimicrob Agents Chemother 1997; 41:2699-704; PMID:9420041.
50. Lynch SV, Dixon L, Benoit MR, Brodie EL, Keyhan M, Hu P, et al. Role of the rapA gene in controlling antibiotic resistance of Escherichia coli biofilms. Antimicrob Agents Chemother 2007; 51:3650-8; PMID:17664315; http://dx.doi.org/10.1128/ AAC.00601-07
51. Huang DB, Nataro JP, DuPont HL, Kamat PP, Mhatre AD, Okhuysen PC, et al. Enteroaggregative Escherichia coli is a cause of acute diarrheal illness: a meta-analysis. Clin Infect Dis 2006; 43:556-63; PMID:16886146; http://dx.doi.org/10.1086/505869
52. Okeke IN, Nataro JP. Enteroaggregative Escherichia coli. Lancet Infect Dis 2001; 1:304-13; PMID:11871803; http://dx.doi.org/10.1016/S1473-3099(01)00144-X
53. Nataro JP, Kaper JB, Robins-Browne R, Prado V, Vial P, Levine MM. Patterns of adherence of diarrheagenic Escherichia coli to HEp-2 cells. Pediatr Infect Dis J 1987; 6:829-31; PMID:3313248; http://dx.doi. org/10.1097/00006454-198709000-00008
54. Wakimoto N, Nishi J, Sheikh J, Nataro JP, Sarantuya J, Iwashita M, et al. Quantitative biofilm assay using a microtiter plate to screen for enteroaggregative Escherichia coli. Am J Trop Med Hyg 2004; 71:687-90; PMID:15569806.
55. Koronakis V. TolC--the bacterial exit duct for proteins and drugs. FEBS Lett 2003; 555:66-71; PMID:14630321; http://dx.doi.org/10.1016/S0014-5793(03)01125-6
56. Imuta N, Nishi J, Tokuda K, Fujiyama R, Manago K, Iwashita M, et al. The Escherichia coli efflux pump TolC promotes aggregation of enteroaggregative E. coli 042. Infect Immun 2008; 76:1247-56; PMID:18160483; http://dx.doi.org/10.1128/ IAI.00758-07
57. Maira-Litrán T, Allison DG, Gilbert P. Expression of the multiple antibiotic resistance operon (mar) during growth of Escherichia coli as a biofilm. J Appl Microbiol 2000; 88:243-7; PMID:10735992; http:// dx.doi.org/10.1046/j.1365-2672.2000.00963.x
58. Matsumura K, Furukawa S, Ogihara H, Morinaga Y. Roles of multidrug efflux pumps on the biofilm formation of Escherichia coli K-12. Biocontrol Sci 2011; 16:69-72; PMID:21719992; http://dx.doi. org/10.4265/bio.16.69
59. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998; 42:3242-4; PMID:9835520.
60. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183:5385-94; PMID:11514524; http://dx.doi. org/10.1128/JB.183.18.5385-5394.2001
61. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46:1704-13; PMID:12019079; http://dx.doi. org/10.1128/AAC.46.6.1704-1713.2002
62. Wirsching S, Moran GP, Sullivan DJ, Coleman DC, Morschhäuser J. MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob Agents Chemother 2001; 45:3416-21; PMID:11709317; http://dx.doi. org/10.1128/AAC.45.12.3416-3421.2001
63. Chandra J, Mukherjee PK, Leidich SD, Faddoul FF, Hoyer LL, Douglas LJ, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 2001; 80:903-8; PMID:11379893; http:// dx.doi.org/10.1177/00220345010800031101
64. Ramage G, Bachmann S, Patterson TF, Wickes BL, López-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49:973-80; PMID:12039889; http://dx.doi. org/10.1093/jac/dkf049
65. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995; 39:2128-31; PMID:8540729; http://dx.doi.org/10.1128/AAC.39.9.2128
66. Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab 2001; 20:42-4; PMID:11570274.
67. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71:4333-40; PMID:12874310; http://dx.doi.org/10.1128/ IAI.71.8.4333-4340.2003
68. Eaves DJ, Ricci V, Piddock LJ. Expression of acrB, acrF, acrD, marA, and soxS in Salmonella enterica serovar Typhimurium: role in multiple antibiotic resistance. Antimicrob Agents Chemother 2004; 48:1145-50; PMID:15047514; http://dx.doi.org/10.1128/ AAC.48.4.1145-1150.2004
69. Zou Y, Woo J, Ahn J. Cellular and molecular responses of Salmonella Typhimurium to antimicrobial-induced stresses during the planktonic-to-biofilm transition. Lett Appl Microbiol 2012; 55:274-82; PMID:22803575; http://dx.doi.org/10.1111/j.1472-765X.2012.03288.x
70. Tabak M, Scher K, Hartog E, Romling U, Matthews KR, Chikindas ML, et al. Effect of triclosan on Salmonella typhimurium at different growth stages and in biofilms. FEMS Microbiol Lett 2007; 267:200-6; PMID:17156099; http://dx.doi.org/10.1111/j.1574-6968.2006.00547.x
71. Baugh S, Ekanayaka AS, Piddock LJ, Webber MA. Loss of or inhibition of all multidrug resistance efflux pumps of Salmonella enterica serovar Typhimurium results in impaired ability to form a biofilm. J Antimicrob Chemother 2012; 67:2409-17; PMID:22733653; http://dx.doi.org/10.1093/jac/dks228
72. Perl TM. The threat of vancomycin resistance. Am J Med 1999; 106(5A):26S-37S, discussion 48S-52S; PMID:10348061; http://dx.doi.org/10.1016/S0002-9343(98)00354-4
73. Ding Y, Onodera Y, Lee JC, Hooper DC. NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J Bacteriol 2008; 190:7123-9; PMID:18723624; http://dx.doi. org/10.1128/JB.00655-08
74. Weigel LM, Donlan RM, Shin DH, Jensen B, Clark NC, McDougal LK, et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007; 51:231-8; PMID:17074796; http://dx.doi. org/10.1128/AAC.00576-06
75. Zhu X, Long F, Chen Y, Knøchel S, She Q, Shi X. A putative ABC transporter is involved in negative regulation of biofilm formation by Listeria monocytogenes. Appl Environ Microbiol 2008; 74:7675-83; PMID:18836003; http://dx.doi.org/10.1128/ AEM.01229-08
76. Frank JF, Koffi RA. Surface-adherent growth of Listeria monocytogenes is associated with increased resistance to surfactant sanitizers and heat. J Food Prot 1990; 53:550-4.
77. Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pagès JM. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother 2007; 59:1223-9; PMID:17229832; http://dx.doi.org/10.1093/jac/dkl493
78. Lomovskaya O, Watkins WJ. Efflux pumps: their role in antibacterial drug discovery. Curr Med Chem 2001; 8:1699-711; PMID:11562289; http://dx.doi. org/10.2174/0929867013371743
79. Marquez B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie 2005; 87:1137-47; PMID:15951096; http://dx.doi.org/10.1016/j.biochi. 2005.04.012
80. Schweizer HP. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Expert Opin Drug Discov 2012; 7:633-42; PMID:22607346; http://dx.doi.org/10.1517/17460441.2012.688949
81. Pagès JM, Amaral L. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta 2009; 1794:826-33; PMID:19150515; http://dx.doi. org/10.1016/j.bbapap.2008.12.011
82. Kvist M, Hancock V, Klemm P. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol 2008; 74:7376-82; PMID:18836028; http://dx.doi.org/10.1128/ AEM.01310-08
83. Fiamegos YC, Kastritis PL, Exarchou V, Han H, Bonvin AM, Vervoort J, et al. Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria. PLoS One 2011; 6:e18127; PMID:21483731; http://dx.doi.org/10.1371/journal.pone.0018127